<DOC>
	<DOCNO>NCT00141713</DOCNO>
	<brief_summary>Etanercept ( Enbrel ) add standard therapy acute Graft-versus-Host Disease see effectiveness standard therapy improve . Partial Funding Source- FDA OOPD</brief_summary>
	<brief_title>The Use Etanercept ( EnbrelÂ® ) Treatment Acute Graft-Versus-Host Disease</brief_title>
	<detailed_description>The standard treatment acute graft-versus-host disease combination steroid tacrolimus cyclosporine . Previous work show less 50 % patient respond fully GVHD . Without good response , patient often prolonged treatment disease , often involve hospitalization sometimes even death . Etanercept drug block chemical call Tumor Necrosis Factor ( TNF ) cause damage tissue . Etanercept ( Enbrel ) add help improve response standard treatment graft-versus-host disease ( GVHD ) . This experimental research project . It know whether etanercept actually improve body 's response graft-versus-host disease . This treatment mean determine etanercept improve response treatment GVHD .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patient may transplant stem cell source use either myeloablative nonmyeloablative preparative regimen Patient may age Patient must biopsy proven new onset aGVHD ; Clinical Grading must IIIV may occur stem cell transplant donor leukocyte infusion ( DLI ) . Patients may begin Etanercept treatment prior biopsy confirmation GVHD . Acute GVHD determine clinical presentation time stem cell infusion Patient must solumedrol dose 2mg/kg/day actual body weight 72 hour prior initiation etanercept Patient must evidence neutrophil engraftment ANC &gt; 500 three consecutive day Pulse ox &gt; 90 % room air Pregnancy nursing mother Intolerance allergic reaction etanercept Previous use steroid treatment acute GVHD Active infection , chronic localize , respond antibiotic , continue sign infection ( patient positive C. Difficile test exclude study ) Condition might predispose develop serious infection ( i.e . active uncontrolled diabetes mellitus , sickle cell anemia ) Other investigational agent treatment prophylaxis graftvshost disease within past 2 week Serum creatinine &gt; 2.0mg/dl Patients treat acute pulmonary dysfunction ( IPS ) study use etanercept Patients hypotension believe secondary sepsis syndrome heart failure require &gt; 1 inotropic agent , dopamine &gt; 5mcg/kg/minute blood pressure support Evidence congestive heart failure clinical exam Evidence hepatic dysfunction ALT AST &gt; 2.5 x ULN , due GVHD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>